PT  - JOURNAL ARTICLE
AU  - Emma Mendelsohn
AU  - Noam Ross
AU  - Allison M. White
AU  - Karissa Whiting
AU  - Cale Basaraba
AU  - Brooke Watson Madubuonwu
AU  - Erica Johnson
AU  - Mushtaq Dualeh
AU  - Zach Matson
AU  - Sonia Dattaray
AU  - Nchedochukwu Ezeokoli
AU  - Melanie Kirshenbaum Lieberman
AU  - Jacob Kotcher
AU  - Samantha Maher
AU  - Carlos Zambrana-Torrelio
AU  - Peter Daszak
TI  - Extracting novel antimicrobial emergence events from scientific literature and medical reports
AID  - 10.1101/2020.08.13.20165852
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.13.20165852
4099  - http://medrxiv.org/content/early/2020/08/15/2020.08.13.20165852.short
4100  - http://medrxiv.org/content/early/2020/08/15/2020.08.13.20165852.full
AB  - Despite considerable global surveillance of antimicrobial resistance (AMR), data on the global emergence of new resistance genotypes in bacteria has not been systematically compiled. We conducted a study of English-language scientific literature (2006-2017) and disease surveillance reports (1994-2017) to identify global events of novel AMR emergence (first clinical reports of unique drug-bacteria resistance combinations). We screened 24,966 abstracts and reports, ultimately identifying 1,773 novel AMR emergence events from 294 articles. Events were reported in 66 countries, with most events in the United States (152), India (129), and China (128). The most common bacteria demonstrating new resistance were Klebsiella pneumoniae (352) and Escherichia coli (218). Resistance was most common against antibiotic drugs imipenem (89 events), ciprofloxacin (85) and ceftazidime (82). We provide an open-access database of emergence events with standardized fields for bacterial species, drugs, location, and date, and we discuss guidelines and caveats for data analysis. This database may be broadly useful for understanding rates and patterns of AMR evolution, identifying global drivers and correlates, and targeting surveillance and interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible by the generous support of the American people through the United States Agency for International Development (USAID) Emerging Pandemic Threats PREDICT (Cooperative Agreement No. AID-OAA0A-14-00102). The contents are the responsibility of the authors and do not necessarily reflect the views or the policy of USAID or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available https://zenodo.org/record/3964895